39 results on '"Ueno, N.T."'
Search Results
2. Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay
3. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
4. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
5. 185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
6. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
7. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
8. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
9. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
10. Identifying factors that impact survival among women with inflammatory breast cancer
11. Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS
12. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
13. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
14. Incidence of and survival following brain metastases among women with inflammatory breast cancer
15. Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer
16. Circulating tumor cells in metastatic inflammatory breast cancer
17. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
18. 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
19. 10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer
20. 98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
21. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma
22. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
23. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
24. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
25. Landscape of somatic mutations in 560 breast cancer whole-genome sequences
26. Landscape of somatic mutations in 560 breast cancer whole-genome sequences
27. Investigator-Initiated Trial for PMDA Approval in Collaboration with the US NCI/CTEP
28. Medical Oncology Training Programs At the University of Texas MD Anderson Cancer Center Need for Clinical Cancer Biologists to Advance the Field of Medical Oncology
29. Medical Oncology Training Programs in the United States
30. Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer
31. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
32. 280: Serological Evidence of Hepatitis C is Associated with Worse Non-Relapse Mortality and Overall Survival after Allogeneic Stem Cell Transplantation
33. 247: High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy for High-Risk Breast Cancer: Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Trials
34. Reduced-intensity conditioning (RIC) regimens result in low prevalence of premature ovarian failure (POF) in women underwent hematopoietic stem-cell transplantation (HST)
35. Allogeneic Hematopoietic Cell Transplantation (Allo HCT) for Metastatic Breast Cancer (MBC)
36. High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy for High-Risk Breast Cancer: Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Trials
37. 15 - Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS
38. 27P The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes.
39. Serological Evidence of Hepatitis C is Associated with Worse Non-Relapse Mortality and Overall Survival after Allogeneic Stem Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.